TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02386475

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sinemet plus
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sinemet plus
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
Study: NCT04249245

Intervention type: OTHER
Intervention: Nasal Swab
Description: All

Intervention type: OTHER
Intervention: Nasal Swab
Description: All
Study: NCT04475146

Intervention type: OTHER
Intervention: video vizualisation
Description: video vizualisation
Study: NCT04506411

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmipure GOLD®
Description: TPG: Turmipure GOLD® capsules - 4 capsules once daily- as prescribed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric rhizome PE 95% curcuminoids
Description: STE: Turmeric rhizome PE 95% curcuminoids - 4 capsules once daily- as prescribed

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Maltodextrin - 4 capsules once daily- as prescribed
Study: NCT03583814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CASE Program
Description: Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CASE Program
Description: Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school or remote asthma education for school aged children, after-school or remote education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HARP Program
Description: Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits or remote sessions (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
Study: NCT01507818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ivivi Torino II
Description: Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0\>

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Sham device
Description: The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
Study: NCT00075647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01616056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft versus host disease prophylaxis/therapy
Description: Wear bandage lenses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography
Description: Optional ancillary studies
Study: NCT00873314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Activity restriction
Description: Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
Study: NCT02475902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer guided home exercise program
Description: Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper guided home exercise program
Description: Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
Study: NCT01115296

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938 and ATCC PTA 6475
Description: L. reuteri dose of 1x108 CFU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01882933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
Description: After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Curative gastrectomy
Description: All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curative gastrectomy
Description: All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
Study: NCT03305731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activating Behavior for Lasting Engagement
Description: Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
Study: NCT01532726

Intervention type: DRUG
Intervention: ESL
Description: ESL 400/800/1200 mg tablets once daily
Study: NCT02925026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysozyme

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02052830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wise Guys
Description: Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
Study: NCT03690648

Intervention type: OTHER
Intervention: Quality of life survey
Description: Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD

Intervention type: OTHER
Intervention: Quality of life survey
Description: Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
Study: NCT04434937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits
Study: NCT03690648

Intervention type: GENETIC
Intervention: Saliva collection
Description: Collection of 20 ml of saliva with a kit of saliva collection

Intervention type: GENETIC
Intervention: Saliva collection
Description: Collection of 20 ml of saliva with a kit of saliva collection

Intervention type: GENETIC
Intervention: Blood collection
Description: Collection of 20 ml of blood with kit of blood collection
Study: NCT00000263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 g/Kg ethanol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 g/KG ethanol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0 g/Kg ethanol
Study: NCT00277706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FORTEO
Description: parathyroid hormone; self-administration for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo; self administration for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium
Description: PO, QD, for six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D and Calcium
Description: PO, QD, for six weeks
Study: NCT04084470

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Different types of bread
Description: Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Different types of bread
Description: Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.
Study: NCT02745743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1251152
Description: Weekly infusion of BAY1251152 in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1251152
Description: Weekly infusion of BAY1251152 in 21-day cycles.
Study: NCT01831856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1g of F373280
Description: Oral administration, one capsule each evening with dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, one capsule each evening with dinner.
Study: NCT01586000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 µg/day E2 with NES 200® µg/day
Description: 10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 µg/day E2 with NES 200® µg/day
Description: 20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 µg/day E2 with NES 200® µg/day
Description: 40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
Study: NCT02295657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard double-lumen tube
Description: intubation using standard double-lumen tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight Double Lumen Tube
Description: intubation using VivaSight Double Lumen Tube
Study: NCT01498653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698/GW642444
Description: ICS/LABA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCI18781
Description: ICS
Study: NCT03672656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lasercoagulation by Pascal system
Description: pattern scanning laser system Pascal given in a single-session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laser
Description: conventional laser multiple-session treatment
Study: NCT02587637

Intervention type: DEVICE
Group type: OTHER
Intervention: Dorsal root ganglion (DRG) stimulation
Description: The role the DRG plays in the development and maintenance of chronic pain, we have developed a neurostimulator system for the management of chronic intractable pain by electrically stimulating the DRG
Study: NCT01679574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: •Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: •Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: •Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
Study: NCT03495570

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
Study: NCT01124409

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EPID Verification
Description: Set up error verification and correction by EPID

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CBCT verification
Description: Setup error verification and correction by CBCT
Study: NCT00580346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of laryngeal implant
Description: Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
Study: NCT03015818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT
Description: 18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
Study: NCT01959516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium capsule for inhalation once per day via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium capsule for inhalation once per day via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium capsule for inhalation once per day via HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium capsule for inhalation once per day via HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glycopyrronium
Description: Placebo to glycopyrronium capsule for inhalation once per day via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to glycopyrronium
Description: Placebo to glycopyrronium capsule for inhalation once per day via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Description: Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
Study: NCT04413123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib predetermined protocol dosage po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab predetermined protocol dosage via IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab predetermined protocol dosage via IV every 3 weeks
Study: NCT03174548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: solution~Route of administration: oral
Study: NCT01765465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rowachol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02931799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Follow-Up
Description: Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Monitoring
Description: Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~* PRO-2 Scale for patients with Crohn's Disease~* 6-Point Mayo Score for patients with Ulcerative Colitis~* Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Discharge Questionnaire
Description: Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Discharge Questionnaire
Description: Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
Study: NCT00336895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 360mg or 720 mg BID for 90 days.
Study: NCT00509808

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrostimulation
Description: 1. 1st month GN wearing (activated or sham mode)~2. 2nd month wearing (opposite mode)~3. 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~4. 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~5. 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes
Study: NCT02703493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
Study: NCT04854668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 7.5mg/kg, intravenous drip, on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, intravenous drip, on Day 1；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, intravenous drip, on Day 1；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
Study: NCT00936546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Mabthera, Rituximab 1000 mg I.V.
Study: NCT02294227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.